Chemistry:Eplerenone

From HandWiki
Short description: Chemical compound
Eplerenone
Eplerenone.svg
Clinical data
Pronunciation/ɛpˈlɛrənoʊn/
Trade namesInspra, Epnone, Dosterep
Other namesSC-66110; CGP-30083; 9-11α-Epoxymexrenone; 9,11α-Epoxy-7α-methoxycarbonyl-3-oxo-17α-pregn-4-ene-21,17-carbolactone
AHFS/Drugs.comMonograph
MedlinePlusa603004
Pregnancy
category
  • AU: B3
  • US: B (No risk in non-human studies)
Routes of
administration		By mouth (tablets)
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability~70%[1]
Protein binding~50% (33–60%) (primarily to α1-acid glycoprotein)[1][2]
MetabolismLiver (CYP3A4)[1][2]
Metabolites6β-OH-EPL, 6β,21-OH-EPL, 21-OH-EPL, 3α,6β-OH-EPL[1] (All inactive)[1]
Elimination half-life4–6 hours[3]
ExcretionUrine (67%), feces (32%)[4]
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
Chemical and physical data
FormulaC24H30O6
Molar mass414.498 g·mol−1
3D model (JSmol)
  (verify)

Eplerenone, sold under the brand name Inspra, is an aldosterone antagonist type of potassium-sparing diuretic that is used to treat chronic heart failure and high blood pressure, particularly for patients with resistant hypertension due to elevated aldosterone. It is a steroidal antimineralocorticoid of the spirolactone group and a selective aldosterone receptor antagonist (SARA).[5] Eplerenone is more selective than spironolactone at the mineralocorticoid receptor relative to binding at androgen, progestogen, glucocorticoid, or estrogen receptors.

Medical uses

Heart failure

Eplerenone reduces risk of death in patients with heart failure,[6] particularly in patients with recent myocardial infarction (heart attack).[7]

Hypertension

Eplerenone lowers blood pressure in patients with primary hypertension.[8] Eplerenone also reduces arterial stiffness and vascular endothelial dysfunction.[9]

For persons with resistant hypertension, eplerenone is safe and effective for reducing blood pressure,[10] particularly in persons with resistant hypertension due to hyperaldosteronism.[11][12]

Central serous chorioretinopathy

Eplerenone is often prescribed for people with central serous chorioretinopathy (CSC). However, the most recent and largest randomized controlled trial showed that eplerenone has no significant effect on chronic CSC that has been untreated for four months.[13][14]

Adverse effects

Common adverse drug reactions (ADRs) associated with the use of eplerenone include: hyperkalaemia, hypotension, dizziness, and reduced renal clearance.[15] Eplerenone may have a lower incidence than spironolactone of sexual side effects such as feminization, gynecomastia, impotence, low sex drive and reduction of size of male genitalia.[16] This is because other antimineralocorticoids have structural elements of the progesterone molecule, causing progestogenic and antiandrogenic outcomes.[3] When considering taking these medicines, it is important to note the variations in their ability to offset the nongenomic effects of aldosterone.[3]

Currently, there is not enough evidence available from the randomized controlled trials on side effects of eplerenone to do a benefit versus risk assessment in people with primary hypertension.[17]

Interactions

Eplerenone is primarily metabolized by the cytochrome P450 enzyme CYP3A4. Thus the potential exists for adverse drug interactions with other drugs that induce or inhibit CYP3A4. Specifically, the concomitant use of the CYP3A4 potent inhibitors ketoconazole and itraconazole is contraindicated. Other CYP3A4 inhibitors including erythromycin, saquinavir, and verapamil should be used with caution. Other drugs that increase potassium concentrations may increase the risk of hyperkalemia associated with eplerenone therapy, including salt substitutes,[18] potassium supplements and other potassium-sparing diuretics.

Pharmacology

Eplerenone is an antimineralocorticoid, or an antagonist of the mineralocorticoid receptor (MR).[19] Eplerenone is also known chemically as 9,11α-epoxy-7α-methoxycarbonyl-3-oxo-17α-pregn-4-ene-21,17-carbolactone and "was derived from spironolactone by the introduction of a 9α,11α-epoxy bridge and by substitution of the 17α-thoacetyl group of spironolactone with a carbomethoxy group."[20] The drug controls high blood pressure by blocking the binding of aldosterone to the mineralocorticoid receptor (MR) in epithelial tissues, such as the kidney.[3] Blocking the action of aldosterone decreases blood volume and lowers blood pressure.[21] It has 10- to 20-fold lower affinity for the MR relative to spironolactone,[19] and is less potent in vivo as an antimineralocorticoid.[3] However, in contrast to spironolactone, eplerenone has little affinity for the androgen, progesterone, and glucocorticoid receptors.[19][3] It also has more consistently observed non-genomic antimineralocorticoid effects relative to spironolactone (see membrane mineralocorticoid receptor).[3] Eplerenone differs from spironolactone in its extensive metabolism, with a short half-life and inactive metabolites.[3]

Eplerenone seems to be about 50 to 75% as potent as spironolactone as an antimineralocorticoid.[22] Hence, 25 mg/day spironolactone may be equivalent to approximately 50 mg/day eplerenone.[23]

Regulatory and Patent History

Eplerenone was patented in 1983 and approved for medical use in the United States in 2002.[24][21] Eplerenone is currently approved for sale in Canada, the US, EU, Netherlands and Japan.[21] Eplerenone costs an estimated $2.93 per day when treating congestive heart failure and $5.86 per day when treating hypertension.[16]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. 24 January 2012. pp. 743–. ISBN 978-1-60913-345-0. https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA743. 
  2. ↑ 2.0 2.1 "Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis". Heart Failure Reviews 10 (1): 23–9. January 2005. doi:10.1007/s10741-005-2345-1. PMID 15947888. 
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 "A comparison of the aldosterone-blocking agents eplerenone and spironolactone". Clinical Cardiology 31 (4): 153–8. April 2008. doi:10.1002/clc.20324. PMID 18404673. 
  4. ↑ Current Cardiovascular Drugs. Springer Science & Business Media. 4 January 2005. pp. 246–. ISBN 978-1-57340-221-7. https://books.google.com/books?id=y3R1Vd3NHqcC&pg=PA246. 
  5. ↑ "Eplerenone: a selective aldosterone receptor antagonist (SARA)". Cardiovascular Drug Reviews 19 (3): 185–200. 2001. doi:10.1111/j.1527-3466.2001.tb00064.x. PMID 11607037. 
  6. ↑ "Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials". Heart Fail Rev 25 (2): 161–171. March 2020. doi:10.1007/s10741-019-09832-y. PMID 31364027. 
  7. ↑ "Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence". Cardiovasc Drugs Ther 34 (5): 723–735. October 2020. doi:10.1007/s10557-020-07027-4. PMID 32564304. 
  8. ↑ "Eplerenone for hypertension". The Cochrane Database of Systematic Reviews 2017 (2): CD008996. February 2017. doi:10.1002/14651858.CD008996.pub2. PMID 28245343. 
  9. ↑ "Effect of Mineralocorticoid Receptor Blockade on Arterial Stiffness and Endothelial Function: A Meta-Analysis of Randomized Trials". Hypertension 77 (3): 929–937. March 2021. doi:10.1161/HYPERTENSIONAHA.120.16397. PMID 33461316. 
  10. ↑ "The Effects of Aldosterone Antagonists in Patients With Resistant Hypertension: A Meta-Analysis of Randomized and Nonrandomized Studies". American Journal of Hypertension 28 (11): 1376–85. November 2015. doi:10.1093/ajh/hpv031. PMID 25801902. 
  11. ↑ "Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension". Hypertens Res 43 (8): 744–753. August 2020. doi:10.1038/s41440-020-0468-3. PMID 32424201. 
  12. ↑ "Rational Medical Therapy Is the Key to Effective Cardiovascular Disease Prevention". The Canadian Journal of Cardiology 33 (5): 626–634. May 2017. doi:10.1016/j.cjca.2017.01.003. PMID 28449833. 
  13. ↑ "Eplerenone does not improve vision in people with central serous chorioretinopathy" (in en). NIHR Evidence (National Institute for Health and Care Research). 2020-03-25. doi:10.3310/signal-000893. https://evidence.nihr.ac.uk/alert/eplerenone-does-not-improve-vision-in-people-with-central-serous-chorioretinopathy/. 
  14. ↑ "Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial". Lancet 395 (10220): 294–303. January 2020. doi:10.1016/S0140-6736(19)32981-2. PMID 31982075. 
  15. ↑ Australian Medicines Handbook 2006. Australian Medicines Handbook. 2006. ISBN 978-0-9757919-2-9. 
  16. ↑ 16.0 16.1 "Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure". Proceedings 17 (2): 217–20. April 2004. doi:10.1080/08998280.2004.11927973. PMID 16200104. 
  17. ↑ "Eplerenone for hypertension". The Cochrane Database of Systematic Reviews 2017 (2): CD008996. February 2017. doi:10.1002/14651858.CD008996.pub2. PMID 28245343. 
  18. ↑ LoSalt Advisory Statement (PDF)
  19. ↑ 19.0 19.1 19.2 "Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology". Kidney International 57 (4): 1408–11. April 2000. doi:10.1046/j.1523-1755.2000.00983.x. PMID 10760075. 
  20. ↑ "Eplerenone: cardiovascular protection". Circulation 107 (19): 2512–8. May 2003. doi:10.1161/01.CIR.0000071081.35693.9A. PMID 12756192. 
  21. ↑ 21.0 21.1 21.2 "Inspra (Eplerenone)". http://www.drugdevelopment-technology.com/projects/inspraeplerenonefort/. 
  22. ↑ "A comparison of the aldosterone-blocking agents eplerenone and spironolactone". Clin Cardiol 31 (4): 153–8. April 2008. doi:10.1002/clc.20324. PMID 18404673. 
  23. ↑ Peter L. Thompson (28 January 2011). Coronary Care Manual. Elsevier Health Sciences. pp. 254–. ISBN 978-0-7295-7927-8. https://books.google.com/books?id=QEltbLcmIN8C&pg=PA254. 
  24. ↑ (in en) Analogue-based Drug Discovery. John Wiley & Sons. 2006. p. 459. ISBN 9783527607495. https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA459. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Eplerenone&oldid=3422353"